LTS AccuTip Microneedle Array Patch Platform

AccuTip stands apart as a breakthrough innovation because it does not incrementally improve drug delivery—it replaces injection dependence with a fully integrated, scalable alternative. By combining delivery, device, and packaging into a single dissolvable microneedle patch, it eliminates pain, sharps waste, dosing variability, and the need for trained administration, directly addressing multiple systemic challenges at once.Its novelty lies in embedding APIs within precisely engineered microneedle tips, enabling consistent intradermal delivery across an exceptional range of modalities—including mRNA, biologics, vaccines, and small molecules—within a tunable, microfabricated system. Unlike many emerging technologies, AccuTip is designed for real-world deployment, with processes built for seamless scale-up to GMP manufacturing.Crucially, AccuTip is validated by performance. It has demonstrated systemic exposure comparable to injections for biologics and superior immune responses versus intramuscular vaccination—without adjuvant—proving that improved usability enhances, rather than compromises, outcomes.Beyond delivery, it redefines packaging and access. Demonstrated stability of mRNA formulations at 2–8°C versus -80°C reduces cold-chain dependence, enabling broader global reach.What makes AccuTip award-worthy is its completeness: it simultaneously advances clinical performance, patient experience, manufacturability, and distribution. It is not a single innovation, but a platform capable of transforming how therapies are delivered worldwide.